Skip to content

Predicting response to biologics in inflammatory bowel disease

Predicting response to biologics in inflammatory bowel disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12613001292763
Enrollment
103
Registered
2013-11-21
Start date
2013-10-01
Completion date
2014-12-16
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Biologic agents have improved disease outcome for many patients with the inflammatory bowel diseases Crohn's disease and ulcerative colitis. However, about 50% patients fail to respond or lose response to treatment. There is some evidence that treatment failure correlates with low biologic drug trough concentrations and/or the presence of anti-drug antibodies. This study aims to examine this correlation in IBD patients in New Zealand with a view to using measurement of drug concentrations and anti-drug antibodies in those who are failing treatment to guide treatment decisions.

Interventions

This is an observational study. Patients receiving biologic therapy for treatment of inflammatory bowel disease will be recruited. Disease activity will be recorded prior to therapy and during therapy. Blood samples will be collected just prior to a dose to measure concentrations of biologic drug and anti-drug antibodies, and both will be correlated with disease activity. This includes CDAI, HBI and SCCAI. Patients will be seen for blood samples and to record disease activity on between 1 or 3 o

This is an observational study. Patients receiving biologic therapy for treatment of inflammatory bowel disease will be recruited. Disease activity will be recorded prior to therapy and during therapy. Blood samples will be collected just prior to a dose to measure concentrations of biologic drug and anti-drug antibodies, and both will be correlated with disease activity. This includes CDAI, HBI and SCCAI. Patients will be seen for blood samples and to record disease activity on between 1 or 3 occasions after starting therapy, after at least 12 weeks of therapy, when they are failing therapy and again if they change to a second biologic drug, after at least 12 weeks.

Sponsors

University of Otago Christchurch
Lead SponsorUniversity

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients with inflammatory bowel disease as determined by standard clinical and endoscopic criteria

Exclusion criteria

Unwilling to provide informed consent

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026